Dec 12, 2019
Kindred Biosciences Announces European Commission Approval of Mirataz® 20 mg/g Transdermal Ointment for Cats Experiencing Poor Appetite and Weight Loss
Nov 12, 2019
Kindred Biosciences Announces Third Quarter 2019 Financial Results
Oct 10, 2019
Kindred Biosciences Announces Positive Opinion from CVMP in the European Union for Mirataz® (mirtazapine transdermal ointment) for Cats Experiencing Poor Appetite and Weight Loss
Apr 25, 2019
Kindred Biosciences to Announce First Quarter 2019 Financial Results
Feb 19, 2019
Kindred Biosciences to Announce Fourth Quarter and Year-End 2018 Financial Results
Jan 22, 2019
Kindred Biosciences Named Best Company in North America by Leading Industry Publication
Jan 14, 2019
Kindred Biosciences Announces Positive Results from Pilot Field Effectiveness Study of epoCat(TM) for the Management of Non-Regenerative Anemia in Cats and Availability of Mirataz® at Banfield Pet Hospital
Nov 07, 2018
Kindred Biosciences Announces Third Quarter 2018 Financial Results
Oct 24, 2018
Kindred Biosciences to Announce Third Quarter 2018 Financial Results
Oct 23, 2018
Kindred Biosciences Elects Denise Bevers to its Board of Directors and Promotes Her to President
Aug 21, 2018
Kindred Biosciences to Participate in the B. Riley FBR Annual Healthcare Conference
May 07, 2018
Kindred Biosciences Receives FDA Approval of Mirataz(TM) (mirtazapine transdermal ointment) for the Management of Weight Loss in Cats
May 30, 2017
Kindred Biosciences to Present Data from Six Studies at the 2017 American College of Veterinary Internal Medicine Conference